AR057959A1 - 5-pirazolpiperidinas-(sustituidas) - Google Patents
5-pirazolpiperidinas-(sustituidas)Info
- Publication number
- AR057959A1 AR057959A1 ARP060105326A ARP060105326A AR057959A1 AR 057959 A1 AR057959 A1 AR 057959A1 AR P060105326 A ARP060105326 A AR P060105326A AR P060105326 A ARP060105326 A AR P060105326A AR 057959 A1 AR057959 A1 AR 057959A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- optionally substituted
- aryl
- ring
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- -1 C0-3-C (O) OR ' Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001589 carboacyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la formula (1) son utiles al tratar o prevenir trastornos cognitivos, tales como la Enfermedad de Alzheimer. La presente también abarca composiciones farmacéuticas que comprenden compuestos de la formula (1) así como métodos para tratar desordenes cognitivos, tales como la Enfermedad de Alzheimer. Reivindicacion 1: Los compuestos de la formula (1) esteroisomeros, tautomeros, mezclas de esteroisomeros y/o tautomeros o sales farmacéuticamente aceptables de la misma, en donde el anillo A es arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde cada anillo está sustituido opcionalmente en una posicion sustituible con halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6, hidroxilo, hidroxialquilo, CN, ariloxi, arilalquiloxi, -SO2-(alquilo C1-6), -NR'Rö, alcoxi C1-6, alquilo C0-3-C(O)OR', heteroarilo, heterocicloalquilo, arilo, arilalquilo, o -SO2-NR'Rö, donde cada R' y Rö es independientemente H o alquilo C1-6 o R' y Rö con el átomo al cual están unidas pueden formar un anillo de 3-8 miembros que opcionalmente incluyen un heteroátomo adicional tal como N, O o S; el anillo B es un anillo heteroarilo o heterocicloalquilo, cada uno de los cuales está sustituido opcionalmente en una posicion sustituible con un grupo que es independientemente alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, amino, alquiloamino C1-6, dialquiloamino C1-6, -S(O)0-2R', hidroxilo, hidroxialquilo, halo, haloalquilo C1-2, haloalcoxi C1-2, -NR'C(O)Rö, -NR'SO2Rö, -C(O)R', -CO2R', alquilo-C(O)OC(O)R', -C(O)NR'Rö, oxo, CN, o alquilarilo C0-1, donde el arilo se sustituye opcionalmente con 1-5 grupos independientemente seleccionados de halogeno, alquilo C1-6, -C(O)OR'alcoxi, haloalquilo C1-6, haloalcoxi, hidroxilo, CN, NO2,ariloxi, -S(O)0-2-(alquilo C1-6), -C(O)NR'Rö, -NR'Rö, alcanoilo C1-6, piridilo, fenilo, y -SO2NR'Rö; y R1, R1a, R2 y R2a, son independientemente H, halogeno, alquilo C1-6, alquenilo C2-6 donde el grupo alquenilo es sustituido opcionalmente con uno o más halogenos; alquinilo C2-6, cicloalquilo C3-6, cicloalquilo C3-6-alquilo C1-6, arilo, arilalquilo C1-6, heteroarilo, -CO2R', CONR'Rö, haloalquilo C1-6, donde el grupo haloalquilo se sustituye opcionalmente con alcoxi C1-4, haloalcoxialquilo C1-4, hidroxi alquilo C1-6, alcanoilo C2-6, ariloxi alquilo C1-6, heteroariloxi alquilo C1-6, alquilo C0-6, OC(O)NR'Rö, o alquilo C0-6, -OC(O)-heterocicloalquilo C0-6, en donde cada arilo, heteroarilo y grupo heterocicloalquilo se sustituye opcionalmente con uno o más grupos que son independientemente halogeno, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, halo alquilo C1-4, halo alcoxi C1-4, -C(O)NR'Rö, -NR'Rö, hidroxilo, -O-(CH2)1-2-O-, -C(O)OR', fenilo, piridazinilo, pirazinilo, pirimidinilo, tiazolilo, piridilo, N-metil pirazolilo, N-bencil pirazolilo, oxadiazolilo, oxazolilo o imidazolilo; R3 y R3a son independientemente H, halogeno o alquilo C1-6; R1 y R1a, o R2 y R2a o R3 y R3a se combinan para formar =O o =N-OR, donde R es H, alquilo C1-6, arilo (tal como fenilo) o arilalquilo (tal como bencilo o fenetilo); o R1, y R1a, o R2 y R2a o R3 y R3a juntos con el C al cual están unidos forman el grupo cicloalquilo C3-6 en donde uno de los carbonos es reemplazado opcionalmente con un heteroátomo seleccionado de N, O o S y en donde dicho anillo puede ser opcionalmente sustituido con alquilo C1-6, o R1 y R3 forman un enlace. doble.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74136605P | 2005-12-01 | 2005-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057959A1 true AR057959A1 (es) | 2007-12-26 |
Family
ID=38092841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105326A AR057959A1 (es) | 2005-12-01 | 2006-12-01 | 5-pirazolpiperidinas-(sustituidas) |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7732609B2 (es) |
| EP (1) | EP1957458A2 (es) |
| JP (1) | JP2009518301A (es) |
| KR (1) | KR20080073359A (es) |
| CN (1) | CN101370776A (es) |
| AR (1) | AR057959A1 (es) |
| AU (1) | AU2006320423B2 (es) |
| BR (1) | BRPI0619633A2 (es) |
| CA (1) | CA2632227A1 (es) |
| EA (1) | EA014906B1 (es) |
| EC (1) | ECSP088593A (es) |
| IL (1) | IL190608A0 (es) |
| MA (1) | MA30089B1 (es) |
| MY (1) | MY149422A (es) |
| NZ (1) | NZ568109A (es) |
| PE (1) | PE20071090A1 (es) |
| TW (1) | TW200736255A (es) |
| WO (1) | WO2007064914A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007006010D1 (de) * | 2006-05-31 | 2010-06-02 | Galapagos Nv | Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| US7977368B2 (en) * | 2007-05-25 | 2011-07-12 | Elan Pharmaceuticals, Inc. | Pyrazolopyrrolidines as inhibitors of gamma secretase |
| MX2010010773A (es) | 2008-04-01 | 2011-04-11 | Abbott Gmbh & Co Kg | Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia. |
| TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| EP2411388A2 (en) * | 2009-03-25 | 2012-02-01 | Elan Pharmaceuticals Inc. | Process for the production of fused, tricyclic sulfonamides |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| TW201319049A (zh) | 2011-08-05 | 2013-05-16 | Abbott Gmbh & Co Kg | 胺基□唍、胺基硫□唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途 |
| CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EP3057958B1 (en) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN105992764A (zh) | 2013-10-17 | 2016-10-05 | 艾伯维德国有限责任两合公司 | 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途 |
| CN104059063A (zh) * | 2014-04-03 | 2014-09-24 | 丽水绿氟科技有限公司 | 7,7-二氟-4,5,6,7-四氢吡唑并[4,3-c]吡啶及其衍生物的制备方法 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ292991A (en) * | 1994-10-20 | 1999-02-25 | Pfizer | Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them |
| DE60143041D1 (de) * | 2000-08-10 | 2010-10-21 | Pfizer Italia Srl | Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| ATE417845T1 (de) * | 2001-10-09 | 2009-01-15 | Kyorin Seiyaku Kk | Neue 4-(2-furoyl)-amino-piperidine, zwischenprodukte für deren synthese, verfahren zu deren herstellung und deren medizinische verwendung |
| WO2004060892A1 (ja) | 2002-12-27 | 2004-07-22 | Japan Tobacco Inc. | 縮合ｎ含有ヘテロ環化合物及びその医薬用途 |
| EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| ES2357776T3 (es) | 2004-10-27 | 2011-04-29 | Janssen Pharmaceutica Nv | Moduladores de cannabionoides de tetrahidro piridinil pirazol. |
| DE102005002500A1 (de) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
| CN102030750A (zh) * | 2005-03-22 | 2011-04-27 | 阿斯利康(瑞典)有限公司 | 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物 |
| DE102005016170A1 (de) * | 2005-04-07 | 2006-10-12 | Grünenthal GmbH | 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| JP2009504773A (ja) | 2005-08-19 | 2009-02-05 | エラン ファーマシューティカルズ，インコーポレイテッド | ガンマセクレターゼの架橋ｎ−二環式スルホンアミド阻害剤 |
-
2006
- 2006-12-01 TW TW095144766A patent/TW200736255A/zh unknown
- 2006-12-01 JP JP2008543496A patent/JP2009518301A/ja active Pending
- 2006-12-01 AU AU2006320423A patent/AU2006320423B2/en not_active Ceased
- 2006-12-01 EA EA200801481A patent/EA014906B1/ru not_active IP Right Cessation
- 2006-12-01 AR ARP060105326A patent/AR057959A1/es not_active Application Discontinuation
- 2006-12-01 WO PCT/US2006/046039 patent/WO2007064914A2/en not_active Ceased
- 2006-12-01 KR KR1020087015935A patent/KR20080073359A/ko not_active Ceased
- 2006-12-01 CA CA002632227A patent/CA2632227A1/en not_active Abandoned
- 2006-12-01 EP EP06844721A patent/EP1957458A2/en not_active Withdrawn
- 2006-12-01 NZ NZ568109A patent/NZ568109A/en not_active IP Right Cessation
- 2006-12-01 MY MYPI20081060A patent/MY149422A/en unknown
- 2006-12-01 PE PE2006001542A patent/PE20071090A1/es not_active Application Discontinuation
- 2006-12-01 BR BRPI0619633-0A patent/BRPI0619633A2/pt not_active Application Discontinuation
- 2006-12-01 US US11/566,070 patent/US7732609B2/en not_active Expired - Fee Related
- 2006-12-01 CN CNA2006800451866A patent/CN101370776A/zh active Pending
-
2008
- 2008-04-03 IL IL190608A patent/IL190608A0/en unknown
- 2008-06-26 MA MA31080A patent/MA30089B1/fr unknown
- 2008-07-01 EC EC2008008593A patent/ECSP088593A/es unknown
-
2010
- 2010-06-08 US US12/796,441 patent/US20100267747A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20071090A1 (es) | 2007-10-24 |
| EP1957458A2 (en) | 2008-08-20 |
| IL190608A0 (en) | 2008-11-03 |
| JP2009518301A (ja) | 2009-05-07 |
| TW200736255A (en) | 2007-10-01 |
| AU2006320423A1 (en) | 2007-06-07 |
| CN101370776A (zh) | 2009-02-18 |
| ECSP088593A (es) | 2008-08-29 |
| MY149422A (en) | 2013-08-30 |
| WO2007064914A3 (en) | 2007-12-27 |
| EA200801481A1 (ru) | 2009-02-27 |
| WO2007064914A8 (en) | 2008-05-15 |
| KR20080073359A (ko) | 2008-08-08 |
| AU2006320423B2 (en) | 2012-06-21 |
| MA30089B1 (fr) | 2008-12-01 |
| EA014906B1 (ru) | 2011-02-28 |
| US20100267747A1 (en) | 2010-10-21 |
| US7732609B2 (en) | 2010-06-08 |
| WO2007064914A2 (en) | 2007-06-07 |
| BRPI0619633A2 (pt) | 2011-10-04 |
| US20070155753A1 (en) | 2007-07-05 |
| NZ568109A (en) | 2011-07-29 |
| CA2632227A1 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057959A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| RU2012141706A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств в отношении метаботропных глутаматных рецепторов-842 | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AU2015341913A1 (en) | Pharmaceutical compound | |
| PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
| CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR067845A1 (es) | Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR092288A1 (es) | Ligandos del receptor ep1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |